Azitra (AZTR) CEO acquires Series A preferred shares and warrants

Rhea-AI Filing Summary

Azitra, Inc. President and CEO Francisco D. Salva reported significant insider purchases of derivative securities. On March 18, 2026, he bought 500 shares of Series A Convertible Non-Redeemable Preferred Stock, which has a stated value of $1,000 per share and automatically converts into 8,128.1 shares of common stock per preferred share once specific stockholder approvals and a charter amendment are obtained.

He also purchased 4,064,050 Series B Warrants and 4,064,050 Series C Warrants, each exercisable for common stock at $0.123 per share. The Series B Warrants become exercisable upon stockholder approval and expire 18 months afterward, while the Series C Warrants become exercisable upon stockholder approval and terminate 30 days after Azitra publicly announces data from its planned human cosmetic study using filaggrin technology.

Insider Trade Summary

3 transactions reported

Net Buy 3 txns

Insider Salva Francisco D.

Role President and CEO

Bought 8,128,600 shs ($0.00)

Type	Security	Shares	Price	Value
Purchase	Series A Convertible Non-Redeemable Preferred Stock	500	$0.00	--
Purchase	Series B Warrants	4,064,050	$0.00	--
Purchase	Series C Warrants	4,064,050	$0.00	--

Holdings After Transaction: Series A Convertible Non-Redeemable Preferred Stock — 500 shares (Direct); Series B Warrants — 4,064,050 shares (Direct); Series C Warrants — 4,064,050 shares (Direct)

Footnotes (1)

1. The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date. The Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following the date of stockholder approval. The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salva Francisco D.

(Last) (First) (Middle)

21 BUSINESS PARK DRIVE

(Street)

BRANFORD CONNECTICUT 06405

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Azitra, Inc. [ AZTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Non-Redeemable Preferred Stock	$0.123	03/18/2026		P		500		(1)	(1)	Common Stock	4,064,050	(1)	500	D
Series B Warrants	$0.123	03/18/2026		P		4,064,050		(2)	(2)	Common Stock	4,064,050	(1)	4,064,050	D
Series C Warrants	$0.123	03/18/2026		P		4,064,050		(3)	(3)	Common Stock	4,064,050	(3)	4,064,050	D

Explanation of Responses:

1. The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date.

2. The Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following the date of stockholder approval.

3. The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology.

	/s/ Francisco D. Salva	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider purchases did Azitra (AZTR) CEO Francisco D. Salva report on Form 4?

Francisco D. Salva reported buying 500 shares of Azitra Series A Convertible Preferred Stock and large blocks of Series B and Series C Warrants. All positions are held directly and relate to future issuances of common stock once specified conditions and approvals are met.

How many Azitra (AZTR) Series B and Series C Warrants did the CEO acquire?

The CEO acquired 4,064,050 Series B Warrants and 4,064,050 Series C Warrants. Each warrant series is exercisable into Azitra common stock at $0.123 per share, subject to stockholder approval and distinct expiration terms described in the disclosures.

What are the conversion terms of Azitra (AZTR) Series A Convertible Preferred Stock bought by the CEO?

Each Series A Convertible Preferred share has a stated value of $1,000 and converts into 8,128.1 Azitra common shares. Conversion occurs automatically after required stockholder approvals and a charter amendment are completed, with no expiration date for the preferred stock.

When do Azitra (AZTR) Series B Warrants acquired by the CEO become exercisable and when do they expire?

The Series B Warrants become exercisable once Azitra stockholders approve the required items. These warrants then remain outstanding for 18 months following that stockholder approval date, after which they terminate if not exercised within that period.

What triggers expiration of Azitra (AZTR) Series C Warrants purchased by the CEO?

Series C Warrants become exercisable upon stockholder approval and generally terminate on the 30th calendar day after Azitra publicly announces data from a planned human cosmetic study using filaggrin technology. Certain limited exceptions to this termination timing are also described.

Are the Azitra (AZTR) insider transactions common stock purchases or derivative positions?

The reported insider activity involves derivative securities, not direct common stock purchases. The CEO acquired Series A Convertible Preferred Stock and Series B and C Warrants, all of which are ultimately convertible or exercisable into Azitra common stock under specified prices, approvals, and timing conditions.